Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naive AIDS- or Late-Presenting HIV-Infected Patients.

ABSTRACT:

Background

Since limited data are available, we aimed to compare the efficacy and durability of dolutegravir and darunavir in advanced naïve patients.

Methods

Retrospective multicenter study including AIDS- or late-presenting (def. CD4 ≤ 200/µL) HIV-infected patients starting dolutegravir or ritonavir/cobicistat-boosted darunavir+2NRTIs. Patients were followed from the date of first-line therapy initiation (baseline, BL) to the discontinuation of darunavir or dolutegravir, or for a maximum of 36 months of follow-up.

Results

Overall 308 patients (79.2% males, median age 43 years, 40.3% AIDS-presenters, median CD4 66 cells/µL) were enrolled; 181 (58.8%) and 127 (41.2%) were treated with dolutegravir and darunavir, respectively. Incidence of treatment discontinuation (TD

SUBMITTER: Fabbiani M 

PROVIDER: S-EPMC10224150 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature